The outcomes highlight the advantages of selecting repurposed medications with known safety profiles for biomarker-stratified precision medicine trials and open the door for testing other selective α2A compounds in the cognitive biotype + subgroup of depression. This evidence concerns the gene IGKV2D-29 and depressive disorder.